^Sestili I, Borioni A, Mustazza C, Rodomonte A, Turchetto L, Sbraccia M, Riitano D, Del Giudice MR (2004). “A new synthetic approach of N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide (JTC-801) and its analogues and their pharmacological evaluation as nociceptin receptor (NOP) antagonists”. European journal of medicinal chemistry39 (12): 1047–57. doi:10.1016/j.ejmech.2004.09.009. PMID15571866.
^Muratani T, Minami T, Enomoto U, Sakai M, Okuda-Ashitaka E, Kiyokane K, Mori H, Ito S (2002). “Characterization of nociceptin/orphanin FQ-induced pain responses by the novel receptor antagonist N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl) benzamide monohydrochloride”. The Journal of Pharmacology and Experimental Therapeutics303 (1): 424–30. doi:10.1124/jpet.102.036095. PMID12235279.
^Okuda-Ashitaka E, Minami T, Matsumura S, Takeshima H, Reinscheid RK, Civelli O, Ito S (2006). “The opioid peptide nociceptin/orphanin FQ mediates prostaglandin E2-induced allodynia, tactile pain associated with nerve injury”. The European Journal of Neuroscience23 (4): 995–1004. doi:10.1111/j.1460-9568.2006.04623.x. PMID16519664.
^Mabuchi T, Matsumura S, Okuda-Ashitaka E, Kitano T, Kojima H, Nagano T, Minami T, Ito S (2003). “Attenuation of neuropathic pain by the nociceptin/orphanin FQ antagonist JTC-801 is mediated by inhibition of nitric oxide production”. The European Journal of Neuroscience17 (7): 1384–92. doi:10.1046/j.1460-9568.2003.02575.x. PMID12713641.
^Suyama H, Kawamoto M, Gaus S, Yuge O (2003). “Effect of JTC-801 (nociceptin antagonist) on neuropathic pain in a rat model”. Neuroscience letters351 (3): 133–6. doi:10.1016/S0304-3940(03)00502-0. PMID14623124.
^Tamai H, Sawamura S, Takeda K, Orii R, Hanaoka K (2005). “Anti-allodynic and anti-hyperalgesic effects of nociceptin receptor antagonist, JTC-801, in rats after spinal nerve injury and inflammation”. European Journal of Pharmacology510 (3): 223–8. doi:10.1016/j.ejphar.2005.01.033. PMID15763246.